Kevin Mcculloch Purchases 25,000 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Kevin Mcculloch bought 25,000 shares of the company's stock in a transaction dated Friday, June 13th. The stock was bought at an average cost of $4.38 per share, with a total value of $109,500.00. Following the acquisition, the insider now directly owns 1,708,585 shares of the company's stock, valued at approximately $7,483,602.30. The trade was a 1.48% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Xeris Biopharma Trading Up 1.1%

NASDAQ:XERS traded up $0.05 during trading hours on Monday, hitting $4.40. 1,487,345 shares of the company were exchanged, compared to its average volume of 1,983,970. The stock has a market capitalization of $688.09 million, a price-to-earnings ratio of -9.78 and a beta of 0.71. Xeris Biopharma Holdings, Inc. has a one year low of $2.03 and a one year high of $6.07. The company has a fifty day simple moving average of $4.55 and a 200 day simple moving average of $4.13.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The company had revenue of $57.80 million during the quarter, compared to analyst estimates of $57.61 million. Equities research analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Wall Street Zen cut shares of Xeris Biopharma from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Leerink Partners upped their price target on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a report on Friday, March 7th. HC Wainwright reissued a "buy" rating and set a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Piper Sandler restated a "neutral" rating and set a $4.00 price objective (up previously from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Finally, Oppenheimer increased their target price on Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $6.25.

Institutional Investors Weigh In On Xeris Biopharma

A number of institutional investors have recently modified their holdings of XERS. Nuveen LLC bought a new stake in Xeris Biopharma during the first quarter valued at $12,240,000. Parkman Healthcare Partners LLC grew its stake in Xeris Biopharma by 207.8% during the first quarter. Parkman Healthcare Partners LLC now owns 1,780,454 shares of the company's stock worth $9,775,000 after purchasing an additional 1,201,943 shares during the period. Goldman Sachs Group Inc. grew its stake in Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company's stock worth $15,317,000 after purchasing an additional 1,199,435 shares during the period. Invesco Ltd. increased its holdings in Xeris Biopharma by 1,387.8% in the first quarter. Invesco Ltd. now owns 1,026,838 shares of the company's stock worth $5,637,000 after purchasing an additional 957,822 shares in the last quarter. Finally, Driehaus Capital Management LLC lifted its stake in Xeris Biopharma by 137.6% in the first quarter. Driehaus Capital Management LLC now owns 1,411,540 shares of the company's stock valued at $7,749,000 after buying an additional 817,525 shares during the period. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.